[1]索罗兰,曹明明,李丽,等.肌肉生长抑制素与代谢性疾病的研究进展[J].国际内分泌代谢杂志,2023,43(02):121-123,127.[doi:10.3760/cma.j.cn121383-20211226-12062]
 Suo Luolan,Cao Mingming,Li Li,et al.Relationship between myostatin and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2023,43(02):121-123,127.[doi:10.3760/cma.j.cn121383-20211226-12062]
点击复制

肌肉生长抑制素与代谢性疾病的研究进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年02期
页码:
121-123,127
栏目:
综述
出版日期:
2023-03-20

文章信息/Info

Title:
Relationship between myostatin and metabolic syndrome
作者:
索罗兰曹明明李丽索紫兰
哈尔滨医科大学附属第一医院内分泌科,哈尔滨 150001
Author(s):
Suo Luolan Cao Mingming Li Li Suo Zilan.
Department of Endocrinology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
关键词:
肌肉生长抑制素 代谢性疾病 胰岛素抵抗 肌肉质量
Keywords:
Myostatin Metabolic disease Insulin resistance Muscle mass
DOI:
10.3760/cma.j.cn121383-20211226-12062
摘要:
代谢性疾病指机体的蛋白质、脂肪和碳水化合物等物质出现代谢紊乱,其中胰岛素抵抗是其重要的病理基础。近期发现一种肌源性因子——肌肉生长抑制素,它在胰岛素抵抗人群中高表达,不仅参与骨骼肌的生长分化,还调控机体能量代谢,介导胰岛素抵抗。因此,肌肉生长抑制素可能在代谢性疾病的发生、发展中发挥重要作用,有望成为防治代谢性疾病的新靶点。本文在现有文献的基础上对肌肉生长抑制素与代谢性疾病的研究进展进行综述。
Abstract:
Metabolic diseases refer to metabolic disorders of proteins, fats and carbohydrates in the body, of which insulin resistance is an important pathological basis. Recently, myostatin, a muscle-derived factor, has been found to be highly expressed in people with insulin resistance. It is not only involved in the growth and differentiation of skeletal muscle, but also regulates the body's energy metabolism and mediates insulin resistance. Therefore, myostatin may play an important role in the occurrence and development of metabolic diseases, and is expected to become a new target for the prevention and treatment of metabolic diseases. Based on the existing literature, this article reviews the research progress of myostatin and it's associations with metabolic diseases.

参考文献/References:

[1] Bovolini A,Garcia J,Andrade MA,et al.Metabolic syndrome pathophysiology and predisposingfactors[J].Int J Sports Med,2021,42(3):199-214.DOI:10.1055/a-1263-0898.
[2] Cruz-Jentoft AJ,Bahat G,Bauer J,et al.Writing group for the european working group on Sarcopenia in older People 2(EWGSOP2),and the extended group for EWGSOP2.Sarcopenia:revised European consensus on definition and diagnosis[J].Age Ageing,2019,48(1):16-31.DOI:10.1093/ageing/afy169.
[3] 杨蕾.中老年人肌肉减少症与代谢综合征的相关性及代谢组学研究[D].新疆:新疆医科大学,2020.DOI:10.27433/d.cnki.gxyku.2020.001020.
[4] Pirruccello-Straub M,Jackson J,Wawersik S,et al.Blocking extracellular activation of myostatin as a strategy for treating muscle wasting[J].Sci Rep,2018,8(1):2292.DOI:10.1038/s41598-018-20524-9.
[5] Omosule CL,Phillips CL.Deciphering myostatin's regulatory,metabolic,and developmental influence in skeletal diseases[J].Front Genet,2021,12:662908.DOI:10.3389/fgene.2021.662908.
[6] Rybalka E,Timpani CA,Debruin DA,et al.The failed clinical story of myostatin inhibitors against duchenne muscular dystrophy:exploring the biology behind the battle[J].Cells,2020,9(12):2657.DOI:10.3390/cells9122657.
[7] Liu HH,Mao HG,Dong XY,et al.Expression of MSTN gene and its correlation with pectoralis muscle fiber traits in the domestic pigeons(Columba livia)[J].Poult Sci,2019,98(11):5265-5271.DOI:10.3382/ps/pez399.
[8] Yang S,Li X,Liu X,et al.Parallel comparative proteomics and phosphoproteomics reveal that cattle myostatin regulates phosphorylation of key enzymes in glycogen metabolism and glycolysis pathway[J].Oncotarget,2018,9(13):11352-11370.DOI:10.18632/oncotarget.24250.
[9] Lee J,Kim DH,Lee K.Muscle hyperplasia in Japanese quail by single amino acid deletion in MSTN propeptide[J].Int J Mol Sci,2020,21(4):1504.DOI:10.3390/ijms21041504.
[10] Hu Z,Zhou L,He T.Potential effect of exercise in ameliorating insulin resistance at transcriptome level[J].J Sports Med Phys Fitness,2019,59(1):116-125.DOI:10.23736/S0022-4707.17.07862-8.
[11] Amor M,Itariu BK,Moreno-Viedma V,et al.Serum myostatin is upregulated in obesity and correlates with insulin resistance in humans[J].Exp Clin Endocrinol Diabetes,2019,127(8):550-556.DOI:10.1055/a-0641-5546.
[12] Tournadre A,Vial G,Capel F,et al.Sarcopenia[J].Joint Bone Spine,2019,86(3):309-314.DOI:10.1016/j.jbspin.2018.08.001.
[13] 柳杨青,汪艳芳.敲除MSTN基因可上调骨骼肌胰岛素信号通路并减轻2型DM小鼠胰岛素抵抗[J].中国病理生理杂志,2021,37(11):1957-1964.DOI:10.3969/j.issn.1000-4718.2021.11.005.
[14] Bonala S,Lokireddy S,McFarlane C,et al.Myostatin induces insulin resistance via casitas B-lineage lymphoma b(Cblb)-mediated degradation of insulin receptor substrate 1(IRS1)in response to high calorie diet intake[J].J Biol Chem,2016,291(27):14392.DOI:10.1074/jbc.A113.529925.
[15] Li B,Cui W,Yang J.Enhanced skeletal muscle growth in myostatin-deficient transgenic pigs had improved glucose uptake in stretozotocin-induced diabetes[J].Transgenic Res,2020,29(2):253-261.DOI:10.1007/s11248-020-00194-y.
[16] Yan H,Meng J,Zhang S,et al.Pretreatment of rAAV-mediated expression of myostatin propeptide lowers type 2 diabetes incidence in C57BL/6 mice on a high-fat diet[J].Hum Gene Ther,2019,30(5):661-671.DOI:10.1089/hum.2018.140.
[17] Zambon Azevedo V,Silaghi CA,Maurel T,et al.Impact of sarcopenia on the severity of the liver damage in patients with non-alcoholic fatty liver disease[J].Front Nutr,2022,8:774030.DOI:10.3389/fnut.2021.774030.
[18] Zarfeshani A,Ngo S,Sheppard AM.Leucine alters hepatic glucose/lipid homeostasis via the myostatin-AMP-activated protein kinase pathway-potential implications for nonalcoholic fatty liver disease[J].Clin Epigenetics,2014,6(1):27.DOI:10.1186/1868-7083-6-27.
[19] Verzola D,Milanesi S,Viazzi F,et al.Enhanced myostatin expression and signalling promote tubulointerstitial inflammation in diabetic nephropathy[J].Sci Rep,2020,10(1):6343.DOI:10.1038/s41598-020-62875-2.
[20] Butcher JT,Mintz JD,Larion S,et al.Increased muscle mass protects against hypertension and renal injury in obesity[J].J Am Heart Assoc,2018,7(16):e009358.DOI:10.1161/JAHA.118.009358.
[21] Chung JO,Park SY,Chung DJ,et al.Serum myostatin levels are positively associated with diabetic retinopathy in individuals with type 2 diabetes mellitus[J].J Diabetes Complications,2020,34(7):107592.DOI:10.1016/j.jdiacomp.2020.107592.
[22] Liu J,Wang Y,Lin L.Small molecules for fat combustion:targeting obesity[J].Acta Pharm Sin B,2019,9(2):220-236.DOI:10.1016/j.apsb.2018.09.007.
[23] 刘兰芳,徐晓阳,齐园圃.衰老对骨骼肌脂代谢的相关调控因子的影响[J].体育科技文献通报,2021,29(12):209-210.DOI:10.19379/j.cnki.issn.1005-0256.2021.12.062.
[24] Buehring B,Binkley N.Myostatin--the holy grail for muscle,bone,and fat?[J].Curr Osteoporos Rep,2013,11(4):407-414.DOI:10.1007/s11914-013-0160-5.
[25] Eilers W,Chambers D,Cleasby M,et al.Local myostatin inhibition improves skeletal muscle glucose uptake in insulin-resistant high-fat diet-fed mice[J].Am J Physiol Endocrinol Metab,2020,319(1):E163-E174.DOI:10.1152/ajpendo.00185.2019.
[26] 伏智亮,沈如玉,王绮绮,等.肌肉生长抑制素调控肌肉和脂肪组织代谢的研究进展[J].畜牧与兽医,2019,51(7):121-126.

相似文献/References:

[1]艾华,谢岚.Irisin与代谢性疾病的关系[J].国际内分泌代谢杂志,2014,(05):316.[doi:10.3760/cma.j.issn.1673-4157.2014.05.008]
 Ai Hua,Xie Lan.Relationship between irisin and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(02):316.[doi:10.3760/cma.j.issn.1673-4157.2014.05.008]
[2]陈恺情,卜瑞芳.Irisin——可否让代谢性疾病治疗进入新时代[J].国际内分泌代谢杂志,2016,36(01):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]
 Chen Kaiqing,Bu Ruifang..Could irisin lead the treatment of metabolic diseases into a new era?[J].International Journal of Endocrinology and Metabolism,2016,36(02):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]
[3]谢绍锋,黄莉吉,王昆,等.南京市城区40岁以上人群超重、肥胖流行 特点调查分析[J].国际内分泌代谢杂志,2016,36(03):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
 Xie Shaofeng*,Huang Liji,Wang Kun,et al.Epidemiological investigation of overweight and obesity in population aged 40 years or older in Nanjing City[J].International Journal of Endocrinology and Metabolism,2016,36(02):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
[4]祝凌妃,杨震,秦利.肌肉因子与代谢性疾病[J].国际内分泌代谢杂志,2016,36(05):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
 Zhu Lingfei,Yang Zhen,Qin li.Myokines and metabolic disease[J].International Journal of Endocrinology and Metabolism,2016,36(02):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
[5]项芬芬,张学梅,高英慧,等.p53与物质能量代谢的关系[J].国际内分泌代谢杂志,2017,37(04):262.
 Xiang Fenfen*,Zhang Xuemei,Gao Yinghui,et al.Relationship between p53 and material, energy metabolism[J].International Journal of Endocrinology and Metabolism,2017,37(02):262.
[6]杨雪 相萍萍 陈国芳 刘超.IGF-1在代谢性疾病中的作用[J].国际内分泌代谢杂志,2018,38(01):33.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
 Yang Xue,Xiang Pingping,Chen Guofang,et al.Effects of IGF-1 in metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(02):33.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
[7]杨雪 韦晓 杨婉薇 陈国芳 刘超.代谢组学在糖尿病研究中的应用[J].国际内分泌代谢杂志,2018,38(05):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
 Yang Xue,Wei Xiao,Yang Wanwei,et al.Application of metabonomics in diabetic research[J].International Journal of Endocrinology and Metabolism,2018,38(02):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
[8]王佳蓓 陈风 刘莹 王涤非.Nur77与物质能量代谢的关系[J].国际内分泌代谢杂志,2019,39(01):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
 Wang Jiabei,Chen Feng,Liu Ying,et al.Relationship between Nur77 and meterial, energy metabolism[J].International Journal of Endocrinology and Metabolism,2019,39(02):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
[9]王雪 朱惠娟 龚凤英.棕色脂肪因子与代谢性疾病[J].国际内分泌代谢杂志,2019,39(06):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
 Wang Xue,Zhu Huijuan,Gong Fengying.Relationship between brown adipocytokine and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2019,39(02):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
[10]王鹏程,姜长涛.肠源神经酰胺与代谢性疾病[J].国际内分泌代谢杂志,2021,41(04):295.[doi:10.3760/cma.j.cn121383-20200610-06029]
 Wang Pengcheng,Jiang Changtao..Relationship between intestinal ceramide and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2021,41(02):295.[doi:10.3760/cma.j.cn121383-20200610-06029]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(82100884); 国家重点研发计划资助(2018YFC1313902)
通信作者:曹明明,Email:mmcao1983@hotmail.com
更新日期/Last Update: 2023-04-15